Fig. 2

Nilotinib augments anti-PDL1 efficacy by enhancing MHC-I expression and amplifying CD8⁺ T-cell-mediated cytotoxicity. A Expression of SIINFEKL-H-2 Kb in MC38-OVA cells following treatment with either 10 μM nilotinib for 48 h or 5 ng/mL IFNγ for 24 h. Subsequently, the MC38-OVA cells treated with 10 μM nilotinib for 48 h were cocultured with OT-I T cells for 12 h, after which the supernatant was collected. B T-cell cytotoxicity was determined by LDH release assay. C IFNγ and TNFα levels were determined by ELISA. D In C57BL/6 mice bearing MC38 xenografts and treated with anti-PDL1 antibody (i.p., 1 mg/kg, every 2 days), nilotinib (orally, 25 mg/kg, daily) or both (N + P), tumor volumes were monitored every other day. E and F After sacrifice, the tumors were weighed and imaged. G H-2 Kb expression levels in tumor samples. H Percentage of CD8⁺ T cells among tumor-infiltrating lymphocytes. I Proportion of IFNγ⁺ cells within the CD8⁺ T-cell population. J In another cohort of C57BL/6 mice bearing MC38 xenografts and treated with the anti-PDL1 antibody, nilotinib, and with or without the CD8a antibody (i.p., 15 mg/kg, every 3 days), tumor volumes were monitored every other day. K and L Following sacrifice, the tumors were weighed and imaged. The results are shown as the mean ± SD. ns. P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001